VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ASCO 2022 | Personalized medicine for patients with GISTs

Michael C. Heinrich, MD, OHSU Knight Cancer Institute, Portland, OR, reflects on emerging biomarkers in predicting treatment responses in patients with gastrointestinal stromal tumors, highlighting the use of circulating tumor DNA (ctDNA) to personalize treatment approaches. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter